D&D Pharmatech Inc. (KOSDAQ:347850)
74,000
+5,300 (7.71%)
Apr 10, 2026, 3:30 PM KST
D&D Pharmatech Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 32,884 | 30,014 | 15,642 | 25,504 | 75,958 |
Short-Term Investments | 0 | - | - | - | - |
Cash & Short-Term Investments | 32,884 | 30,014 | 15,642 | 25,504 | 75,958 |
Cash Growth | 9.56% | 91.88% | -38.67% | -66.42% | 25.32% |
Accounts Receivable | 201.92 | 3,141 | 263.95 | 41.84 | 12.46 |
Other Receivables | 1,773 | 2,383 | 1,165 | 286.31 | 94.12 |
Receivables | 1,975 | 5,524 | 1,429 | 328.15 | 106.58 |
Prepaid Expenses | 996.48 | 4,047 | 2,356 | 7,330 | 5,507 |
Other Current Assets | 15,132 | 209.3 | 138.64 | 193.46 | 121.45 |
Total Current Assets | 50,988 | 39,794 | 19,565 | 33,355 | 81,692 |
Property, Plant & Equipment | 5,636 | 7,729 | 6,422 | 3,024 | 10,966 |
Long-Term Investments | 9,248 | 14,242 | 10,776 | 12,326 | - |
Goodwill | 2,043 | 2,093 | 9,905 | 9,735 | 34,754 |
Other Intangible Assets | 28,308 | 32,476 | 31,615 | 34,246 | 122,689 |
Long-Term Accounts Receivable | 1.56 | 3.84 | 179.43 | 6.72 | 7.68 |
Other Long-Term Assets | 1,315 | 1,162 | 740.73 | 948.44 | 1,000 |
Total Assets | 97,539 | 97,500 | 79,204 | 93,642 | 251,109 |
Accrued Expenses | 940.93 | 4,468 | 2,080 | 6,803 | 7,647 |
Short-Term Debt | - | 1,830 | 1,521 | 19,225 | 34,836 |
Current Portion of Leases | 1,978 | 1,772 | 1,493 | 1,583 | 1,276 |
Other Current Liabilities | 2,500 | 3,044 | 2,393 | 27,312 | 23,100 |
Total Current Liabilities | 5,419 | 11,115 | 7,487 | 54,923 | 66,859 |
Long-Term Leases | 4,267 | 6,180 | 5,121 | 6,425 | 7,463 |
Pension & Post-Retirement Benefits | - | - | 13 | - | 49.7 |
Long-Term Deferred Tax Liabilities | 7,671 | 8,811 | 8,564 | 9,239 | 33,367 |
Other Long-Term Liabilities | 1,204 | 1,825 | 2,801 | 4,536 | 5,042 |
Total Liabilities | 18,560 | 27,931 | 23,986 | 75,123 | 112,781 |
Common Stock | 21,768 | 5,284 | 4,649 | 4,034 | 4,028 |
Additional Paid-In Capital | 333,829 | 337,015 | 297,522 | 268,925 | 268,673 |
Retained Earnings | -332,916 | -309,361 | -289,676 | -293,610 | -157,543 |
Comprehensive Income & Other | 56,813 | 37,174 | 34,154 | 30,091 | 16,951 |
Total Common Equity | 79,494 | 70,112 | 46,650 | 9,440 | 132,109 |
Minority Interest | -514.69 | -542.93 | 8,568 | 9,079 | 6,219 |
Shareholders' Equity | 78,979 | 69,569 | 55,218 | 18,519 | 138,328 |
Total Liabilities & Equity | 97,539 | 97,500 | 79,204 | 93,642 | 251,109 |
Total Debt | 6,245 | 9,782 | 8,134 | 27,233 | 43,575 |
Net Cash (Debt) | 26,639 | 20,231 | 7,508 | -1,729 | 32,383 |
Net Cash Growth | 31.67% | 169.47% | - | - | -40.99% |
Net Cash Per Share | 618.63 | 499.02 | 200.09 | -53.64 | 983.80 |
Filing Date Shares Outstanding | 140.05 | 42.27 | 37.2 | 32.27 | 32.23 |
Total Common Shares Outstanding | 140.05 | 42.27 | 37.2 | 32.27 | 32.23 |
Working Capital | 45,569 | 28,680 | 12,078 | -21,568 | 14,834 |
Book Value Per Share | 567.60 | 1658.58 | 1254.17 | 292.55 | 4099.37 |
Tangible Book Value | 49,143 | 35,544 | 5,129 | -34,541 | -25,333 |
Tangible Book Value Per Share | 350.89 | 840.82 | 137.90 | -1070.43 | -786.09 |
Machinery | 3,148 | 3,198 | 3,250 | 3,441 | 3,454 |
Construction In Progress | - | - | 1.7 | - | 4.78 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.